Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ATYR vs OBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATYR Captures Overall Composite Edge (34.3 SELL vs 43.2 HOLD), While OBIO Leads 3–2 on Growth & Valuation Pillars
ATYR Overall Winner
6-Pillar Tally: ATYR 2 – 3 OBIO (1 Tie)
Matrix Metrics: ATYR 4 – 4 OBIO
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus OBIO at $7.07 (N/M Forward P/E, -195.4% operating margin).
- Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ATYR vs OBIO
ATYR
Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
$4.96
-5.34% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.67β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
$7.07
-0.7% 1D
Market Cap
$570.6M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.15β · 80% Vol
Unified Composite Score
43.2
HOLD
Tech 15.0
Fund 36.0
Flow 62.0
Mom 54.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ATYR 2 – 3 OBIO)
1. Valuation Multiples
OBIO
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
18.6x
2. Growth & Scale
OBIO
Revenue Growth (YoY)
+0.0%
-89.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$31M
Market Cap
$15.6M
$570.6M
3. Profitability & Quality
ATYR
Gross Margin
N/A
99.6%
Operating Margin
0.0%
-195.4%
Net Profit Margin
0.0%
-182.5%
Return on Equity (ROE)
-93.7%
-182.3%
4. Balance Sheet & Cash Flow
ATYR
Cash Generation (TTM)
N/A
-$64M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$9.0M Net Debt (4.72x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OBIO
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
154.5% (36th %ile)
70.8% (<1st %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ATYR (4) vs OBIO (4)| Institutional Metric | ATYR | OBIO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $15.6M | $570.6M | OBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | -89.4% | ATYR | |
| Operating Margin (TTM) | 0.0% | -195.4% | ATYR | |
| Net Profit Margin | 0.0% | -182.5% | ATYR | |
| Return on Equity (ROE) | -93.7% | -182.3% | ATYR | |
| 52-Week Range Position | 62% ($0–$8) | 90% ($3–$7) | OBIO | |
| Beta / 30D Volatility | -9.67β · 13806% Vol | 1.15β · 80% Vol | OBIO | |
| Unified Institutional Score | 34.3 / 100 (SELL) | 43.2 / 100 (HOLD) | OBIO | |
| Trailing 12M Revenue (USD) | N/A | $31M | Scale | |
| Gross Profit Margin (TTM) | N/A | 99.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 18.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($4.9M Net Cash) | -$64M ($9.0M Net Debt (4.72x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2763.63 pp
3M Horizon
ATYR +803.54 pp
6M Horizon
ATYR +850.17 pp
1Y Horizon
ATYR +479.26 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATYR Revenue | OBIO Revenue | ATYR Op. Margin | OBIO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -5445.0% | N/A | ATYR |
| FY2020 | $10M | N/A | -152.2% | N/A | ATYR |
| FY2022 | $10M | $0M | -446.8% | -924.3% | ATYR |
| FY2023 | $0M | $0M | -15557.8% | -1866.2% | OBIO |
| FY2024 | $0M | $0M | -28899.6% | -2437.5% | OBIO |
| FY2025 | $0M | $30M | -40856.3% | -154.7% | OBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
OBIO
BREAKOUT
Current IV
70.8%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
OBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ATYR vs OBIO Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus OBIO at $7.07 (N/M Forward P/E, -195.4% operating margin). Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
OBIO leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), ATYR cumulative revenue shifted +0.0% while OBIO shifted N/A. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.
OBIO screens cheaper on headline valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus OBIO (-182.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
OBIO vs ATYR · Reverse Pair
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
OBIO vs OABI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking